Tumor lysis syndrome signal with the combination of encorafenib and binimetinib for malignant melanoma: a pharmacovigilance study using data from the FAERS database

Tumor lysis syndrome signal with the combination of encorafenib and binimetinib for malignant melanoma: a pharmacovigilance study using data from the FAERS database

ObjectiveTo investigate the potential association between tumor lysis syndrome (TLS) and drugs for the treatment of malignant melanoma (MM).MethodsReports of TLS recorded in the FDA Adverse Event Reporting System (FAERS) (January 2004–2023q3) were identified. Demographic and clinical characteristics...

Full description

Bibliographic Details
Main Authors: Shuang Xia, Jing-Wen Xu, Kang-Xin Yan, Yoshihiro Noguchi, Mayur Sarangdhar, Miao Yan
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-09-01
Series:Frontiers in Pharmacology
Subjects:
encorafenib
binimetinib
tumor lysis syndrome
malignant melanoma
pharmacovigilance
FAERS
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1413154/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1413154/full

Similar Items